IRL files new patent application
The team at IRL have recently discovered a novel class of compounds with specific and precise effects on cortical neurotransmission, useful for the treatment of disorders characterized by cognitive and attentive dysfunctions.
A patent application for this new class was submitted on may 20, 2015. “We are proud to announce a new patent application for this new class of compounds. We will now continue to explore and develop this asset towards a novel and meaningful treatment for attention disorders, says Dr Clas Sonesson, CSO”.